Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Oxygen therapy 79% Improvement Relative Risk c19early.org/o Avanoglu Guler et al. Colchicine for COVID-19 Prophylaxis Is prophylaxis with colchicine beneficial for COVID-19? Retrospective 73 patients in Turkey Lower need for oxygen therapy with colchicine (p=0.043) Avanoglu Guler et al., Modern Rheumatology, doi:10.1093/mr/roac074 Favors colchicine Favors control
COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease
Avanoglu Guler et al., Modern Rheumatology, doi:10.1093/mr/roac074
Avanoglu Guler et al., COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease, Modern Rheumatology, doi:10.1093/mr/roac074
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 73 familial Mediterranean fever patients with COVID-19 in Turkey, showing significantly higher risk of hospitalization for respiratory support with non-adherence to colchicine treatment before the infection.
risk of oxygen therapy, 78.8% lower, RR 0.21, p = 0.04, treatment 6 of 66 (9.1%), control 3 of 7 (42.9%), NNT 3.0, inverted to make RR<1 favor treatment, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Avanoglu Guler et al., 21 Jul 2022, retrospective, Turkey, peer-reviewed, median age 39.5, 14 authors.
Contact: aslihanavanoglu@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Modern Rheumatology, 00, 2022, 1–6 DOI: https://doi.org/10.1093/mr/roac074 Advance Access Publication Date: 21 July 2022 Original Article COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease a Faculty of Medicine Hospital, Department of Rheumatology, Gazi University, Ankara, Turkey Faculty of Medicine Hospital, Department of Rheumatology, Dokuz Eylul University, Izmir, Turkey c Faculty of Medicine Hospital, Department of Rheumatology, Eskisehir Osmangazi University, Eskisehir, Turkey d Faculty of Medicine Hospital, Department of Internal Medicine, Gazi University, Ankara, Tukey b *Correspondence: Aslıhan Avanoglu Guler; aslihanavanoglu@gmail.com; Gazi University, Department of Internal Medicine & Rheumatology, Gazi Universitesi Hastaneleri, Emniyet Mahallesi, Mevlana Bulvarı, Yenimahalle/Ankara 06560, Turkey. ABSTRACT Objectives: To evaluate the impact of familial Mediterranean fever (FMF) features on the clinical course and outcomes of coronavirus disease 2019 (COVID-19) and clinical course of FMF after COVID-19. Methods: Consecutive FMF patients with COVID-19 were enrolled from three referral hospitals. Clinical features of FMF and detailed COVID-19 information were obtained from patient interviews and medical records. Results: Seventy-three FMF patients were included in the study. 94.5% of patients had clinical symptoms of COVID-19. We found 24.7% hospitalization, 12.3% respiratory support, 4.1% intensive care unit admission, 6.8% complication, and 1.4% mortality rate in patients. The risk factors of hospitalization for respiratory support were male gender [OR: 7.167 (95% CI: 1.368–37.535)], greater age [OR: 1.067 (95% CI: 1.016–1.121)], and non-adherence to colchicine treatment before the infection [OR: 7.5 (95% CI: 1.348–41.722)]. One-third of patients had reported attacks after COVID-19. The patterns of triggered attacks were fever, peritonitis, pleuritis, transient arthritis, chronic knee mono-arthritis, and protracted febrile myalgia. Conclusions: FMF characteristics were not associated with worse outcomes of COVID-19. Colchicine non-adherence was the risk factor of hospitalization for oxygen support. The rate of FMF attacks after COVID-19 is prominently increased, with some of them being protracted and destructive. KEYWORDS: Coronovirus-19 disease; familial Mediterranean fever; clinical course; complication; outcome
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit